
2023 Hematology Highlights A Post-ASH Review

Saturday, Feb. 4 • Hilton Omaha 1001 Cass Street, Omaha, NE 68102



The University of Nebraska Medical Center has sponsored this regional conference for the last 16 years. This year's conference is designed to update the target audience on new treatments and management of acute and chronic leukemia, thrombosis/hemostasis, lymphoma, multiple myeloma, myelodysplastic syndromes, and myeloproliferative neoplasms as presented during the 2022 annual meeting of the American Society of Hematology. Presentations will be delivered by key leaders while allowing the opportunity for participants to be involved in the interactive question/answer sessions.

AGENDA

Check In / Continental Breakfast / Exhibits 7:15 a.m.

Welcome / Introductions 7:45 a.m.

Lori Maness-Harris, MD

New Developments with Hemostasis and Thrombosis 8:00 a.m.

Kathryn Hassell, MD

Myelodysplastic Syndromes: Updates from the 2022 8:35 a.m.

> Annual ASH Meeting Amer Zeidan, MBBS, MHS

Myeloproliferative Neoplasms: What We Have 9:10 a.m.

Recently Discovered

Vivian Oehler, MD

9:45 a.m. Advances in Acute Myeloid Leukemia

Wendy Stock, MD

Break / Exhibits 10:20 a.m.

Multiple Myeloma: Updates from the 2022 Annual 10:45 a.m.

> **ASH Meeting** Faith Davies, MD

Updates in Chronic Lymphocytic Leukemia 11:20 a.m.

William Wierda, MD, PhD

Highlights in Lymphoma from the 2022 ASH Annual 11:55 a.m.

Meeting

Christopher D'Angelo, MD

Closing Remarks / Adjourn 12:30 p.m.

R. Gregory Bociek, MD, MSc, FRCP(C)

TARGET AUDIENCE

This accredited continuing education activity is designed for physicians, advanced practice practitioners, pharmacists, nurses, residents, and fellows in the specialty areas of oncology, hematology, internal medicine, radiation oncology, and pathology.

SYMPOSIUM OBJECTIVES

At the conclusion of this activity, the participant should be better able to:

- 1. Articulate the mechanism of action surrounding new therapies and the process for appropriate patient selection when caring for those with hematologic malignancies, as well as non-malignant hematologic disorders.
- 2. Analyze emerging data regarding new clinical, genetic, and molecular prognostic factors, and how to use them for improved precision approaches for the treatment of hematologic malignancies.
- 3. Discuss recent clinical trials demonstrating a reduction of treatment intensity involving therapies such as a combination of pharmacologic strategies when caring for those with hematologic malignancies.
- 4. Summarize the impact of the evidence-based findings from the 2022 Annual ASH Meeting surrounding the management of hematologic malignancies and other disorders of thrombosis and hemostasis in clinical practice.

REGISTRATION INFORMATION

Registration Fees

\$100 — Physicians

\$ 80 — Other health care professionals

FREE — Fellows/residents

The deadline to register online is Jan. 27, 2023.

Once online registration is closed, you will only be able to register on-site for the walk-in fee of \$175. Walk-in registrations will only be accepted if space is available; meals are not guaranteed.

QUESTIONS?

Contact Bailey Wrenn, MA at bailey.wrenn@unmc.edu.

CONTINUING EDUCATION CREDITS



In support of improving patient care, University of Nebraska Medical Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians: The University of Nebraska Medical Center designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: The University of Nebraska Medical Center designates this activity for 4.0 ANCC contact hours. Nurses should only claim credit for the actual time spent participating in the activity.

Pharmacists: The University of Nebraska Medical Center designates this activity for 4.0 ACPE contact hours. Pharmacists should claim only the credit commensurate with the extent of their participation in the activity. Credit will be provided to NABP CPE Monitor within 60 days after the activity completion.

